Disc Medicine Inc (IRON)
$50.35
+0.15
(+0.3%)▲
Performance
- $48.72$51.01$50.35
3.24%
Downside
Day's Volatility :4.49%
Upside
1.29%
- $25.60$77.60$50.35
49.16%
Downside
52 Weeks Volatility :67.01%
Upside
35.12%
Returns
| Period | Disc Medicine Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 28.71% | 0.0% |
6 Months | -19.65% | 0.0% |
1 Year | -6.17% | 0.0% |
3 Years | 921.3% | -22.3% |
Highlights
Market Capitalization | 1.5B |
Book Value | $16.45 |
Earnings Per Share (EPS) | -3.62 |
Wall Street Target Price | 66.1 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -15.51% |
Return On Equity TTM | -21.16% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -110.8M |
Diluted Eps TTM | -3.62 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.51 |
EPS Estimate Next Year | -5.03 |
EPS Estimate Current Quarter | -1.11 |
EPS Estimate Next Quarter | -1.17 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 31.28%
Technicals Summary
Sell
Neutral
Buy
Disc Medicine Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Disc Medicine Inc | 22.0% | -19.65% | -6.17% | 921.3% | 316.12% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Disc Medicine Inc | 4.9 | NA | NA | -4.51 | -0.21 | -0.16 | NA | 16.45 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Disc Medicine Inc | Buy | $1.5B | 316.12% | 4.9 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Disc Medicine Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 43.3%
Company Information
disc medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. focused on the hepcidin pathway, the master regulator of iron metabolism, disc is advancing first-in-class therapies to transform the treatment of hematologic diseases.
Organization | Disc Medicine Inc |
Employees | 78 |
CEO | Dr. Donald William Nicholson Ph.D. |
Industry | Healthcare |
